BACKGROUND: @entity927 (TXA) significantly decreases @entity190 and transfusion rates after total hip and total knee arthroplasty. The purpose of this study was to determine the effects of intravenous TXA on @entity190 and @entity1 outcomes after @entity348 ( @entity348 ). METHODS: TXA was used in 106 consecutive @entity1 undergoing primary anatomic and reverse @entity348 with a dose of 20  mg/kg intravenously (TXA group) and compared with the previous consecutive 88 @entity1 without TXA (non-TXA group). All @entity1 had a blood sample drawn for a hemoglobin and hematocrit determination the morning after surgery. Analysis of variance and   (2) techniques were used to analyze study hypotheses. RESULTS: Statistically significant differences in both hemoglobin loss (TXA group     =  2.13 vs. non-TXA group     =  2.63; P  =  .01) and hematocrit loss (TXA group     =  6.4 vs. non-TXA group     =  8.14; P  <  .01) were seen in the TXA group compared with the non-TXA group. In @entity1 receiving TXA, there were statistically significant decreases in the time spent in the recovery room (mean, TXA group 69  minutes vs. non-TXA group 87  minutes; P  <  .02) and total length of hospitalization (mean, TXA group 1.18  days vs. non-TXA group 1.4  days; P  =  .01). Two @entity1 in the TXA group received a blood transfusion, whereas 6 @entity1 in the non-TXA group did. CONCLUSIONS: TXA 20  mg/kg intravenously given just before primary anatomic and reverse @entity348 results in statistically significant reductions in @entity190 . @entity1 spent 21% less time in the recovery room and had a 16% shorter hospitalization, resulting in financial savings for the hospital.

XXXX decreases @entity190 after @entity348 .

@entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity348 :: ('MESH:C535338', 'Disease') :: ['total shoulder arthroplasty', 'TSA'] @entity927 :: ('MESH:D014148', 'Chemical') :: ['Tranexamic acid']
@entity927 :: (MESH:D014148,Chemical) :: ['Tranexamic acid']
